TY  - JOUR
AU  - Gomes, Clarissa Pedrosa da C
AU  - Ágg, Bence
AU  - Andova, Andrejaana
AU  - Arslan, Serdal
AU  - Baker, Andrew
AU  - Barteková, Monika
AU  - Beis, Dimitris
AU  - Betsou, Fay
AU  - Wettinger, Stephanie Bezzina
AU  - Bugarski, Branko
AU  - Condorelli, Gianluigi
AU  - Silva, Gustavo José Justo da
AU  - Danilin, Sabrina
AU  - de Gonzalo-Calvo, David
AU  - Buil, Alfonso
AU  - Carmo-Fonseca, Maria
AU  - Enguita, Francisco J
AU  - Felekkis, Kyriacos
AU  - Ferdinandy, Peter
AU  - Gyöngyösi, Mariann
AU  - Hackl, Matthias
AU  - Karaduzovic-Hadziabdic, Kanita
AU  - Hellemans, Jan
AU  - Heymans, Stephane
AU  - Hlavackova, Markéta
AU  - Hoydal, Morten Andre
AU  - Janković, Aleksandra
AU  - Jusic, Amela
AU  - Kardassis, Dimitris
AU  - Kerkelä, Risto
AU  - Kuster, Gabriela M
AU  - Lakkisto, Päivi
AU  - Leszek, Przemyslaw
AU  - Lustrek, Mitja
AU  - Maegdefessel, Lars
AU  - Martelli, Fabio
AU  - Novella, Susana
AU  - O'Brien, Timothy
AU  - Papaneophytou, Christos
AU  - Pedrazzini, Thierry
AU  - Pinet, Florence
AU  - Popescu, Octavian
AU  - Potočnjak, Ines
AU  - Robinson, Emma
AU  - Sasson, Shlomo
AU  - Scholz, Markus
AU  - Simionescu, Maya
AU  - Stoll, Monika
AU  - Varga, Zoltan V
AU  - Vinciguerra, Manlio
AU  - Xuereb, Angela
AU  - Yilmaz, Mehmet Birhan
AU  - Emanueli, Costanza
AU  - Devaux, Yvan
AU  - on behalf of the EU-CardioRNA COST Action (CA17129)
PY  - 2019
UR  - https://www.mdpi.com/2311-553X/5/2/31
UR  - http://www.pubmedcentral.nih.gov/articlerender.fcgi?artid=PMC6630366
UR  - https://radar.ibiss.bg.ac.rs/handle/123456789/3443
AB  - Cardiovascular disease (CVD) remains the leading cause of death worldwide and, despite continuous advances, better diagnostic and prognostic tools, as well as therapy, are needed. The human transcriptome, which is the set of all RNA produced in a cell, is much more complex than previously thought and the lack of dialogue between researchers and industrials and consensus on guidelines to generate data make it harder to compare and reproduce results. This European Cooperation in Science and Technology (COST) Action aims to accelerate the understanding of transcriptomics in CVD and further the translation of experimental data into usable applications to improve personalized medicine in this field by creating an interdisciplinary network. It aims to provide opportunities for collaboration between stakeholders from complementary backgrounds, allowing the functions of different RNAs and their interactions to be more rapidly deciphered in the cardiovascular context for translation into the clinic, thus fostering personalized medicine and meeting a current public health challenge. Thus, this Action will advance studies on cardiovascular transcriptomics, generate innovative projects, and consolidate the leadership of European research groups in the field.COST (European Cooperation in Science and Technology) is a funding organization for research and innovation networks (www.cost.eu).
T2  - Non-Coding RNA
T1  - Catalyzing Transcriptomics Research in Cardiovascular Disease: The CardioRNA COST Action CA17129.
IS  - 2
VL  - 5
DO  - 10.3390/ncrna5020031
SP  - 31
ER  - 

@article{
author = "Gomes, Clarissa Pedrosa da C and Ágg, Bence and Andova, Andrejaana and Arslan, Serdal and Baker, Andrew and Barteková, Monika and Beis, Dimitris and Betsou, Fay and Wettinger, Stephanie Bezzina and Bugarski, Branko and Condorelli, Gianluigi and Silva, Gustavo José Justo da and Danilin, Sabrina and de Gonzalo-Calvo, David and Buil, Alfonso and Carmo-Fonseca, Maria and Enguita, Francisco J and Felekkis, Kyriacos and Ferdinandy, Peter and Gyöngyösi, Mariann and Hackl, Matthias and Karaduzovic-Hadziabdic, Kanita and Hellemans, Jan and Heymans, Stephane and Hlavackova, Markéta and Hoydal, Morten Andre and Janković, Aleksandra and Jusic, Amela and Kardassis, Dimitris and Kerkelä, Risto and Kuster, Gabriela M and Lakkisto, Päivi and Leszek, Przemyslaw and Lustrek, Mitja and Maegdefessel, Lars and Martelli, Fabio and Novella, Susana and O'Brien, Timothy and Papaneophytou, Christos and Pedrazzini, Thierry and Pinet, Florence and Popescu, Octavian and Potočnjak, Ines and Robinson, Emma and Sasson, Shlomo and Scholz, Markus and Simionescu, Maya and Stoll, Monika and Varga, Zoltan V and Vinciguerra, Manlio and Xuereb, Angela and Yilmaz, Mehmet Birhan and Emanueli, Costanza and Devaux, Yvan and on behalf of the EU-CardioRNA COST Action (CA17129)",
year = "2019",
abstract = "Cardiovascular disease (CVD) remains the leading cause of death worldwide and, despite continuous advances, better diagnostic and prognostic tools, as well as therapy, are needed. The human transcriptome, which is the set of all RNA produced in a cell, is much more complex than previously thought and the lack of dialogue between researchers and industrials and consensus on guidelines to generate data make it harder to compare and reproduce results. This European Cooperation in Science and Technology (COST) Action aims to accelerate the understanding of transcriptomics in CVD and further the translation of experimental data into usable applications to improve personalized medicine in this field by creating an interdisciplinary network. It aims to provide opportunities for collaboration between stakeholders from complementary backgrounds, allowing the functions of different RNAs and their interactions to be more rapidly deciphered in the cardiovascular context for translation into the clinic, thus fostering personalized medicine and meeting a current public health challenge. Thus, this Action will advance studies on cardiovascular transcriptomics, generate innovative projects, and consolidate the leadership of European research groups in the field.COST (European Cooperation in Science and Technology) is a funding organization for research and innovation networks (www.cost.eu).",
journal = "Non-Coding RNA",
title = "Catalyzing Transcriptomics Research in Cardiovascular Disease: The CardioRNA COST Action CA17129.",
number = "2",
volume = "5",
doi = "10.3390/ncrna5020031",
pages = "31"
}

Gomes, C. P. d. C., Ágg, B., Andova, A., Arslan, S., Baker, A., Barteková, M., Beis, D., Betsou, F., Wettinger, S. B., Bugarski, B., Condorelli, G., Silva, G. J. J. d., Danilin, S., de Gonzalo-Calvo, D., Buil, A., Carmo-Fonseca, M., Enguita, F. J., Felekkis, K., Ferdinandy, P., Gyöngyösi, M., Hackl, M., Karaduzovic-Hadziabdic, K., Hellemans, J., Heymans, S., Hlavackova, M., Hoydal, M. A., Janković, A., Jusic, A., Kardassis, D., Kerkelä, R., Kuster, G. M., Lakkisto, P., Leszek, P., Lustrek, M., Maegdefessel, L., Martelli, F., Novella, S., O'Brien, T., Papaneophytou, C., Pedrazzini, T., Pinet, F., Popescu, O., Potočnjak, I., Robinson, E., Sasson, S., Scholz, M., Simionescu, M., Stoll, M., Varga, Z. V., Vinciguerra, M., Xuereb, A., Yilmaz, M. B., Emanueli, C., Devaux, Y.,& on behalf of the EU-CardioRNA COST Action (CA17129). (2019). Catalyzing Transcriptomics Research in Cardiovascular Disease: The CardioRNA COST Action CA17129.. in Non-Coding RNA, 5(2), 31.
https://doi.org/10.3390/ncrna5020031

Gomes CPDC, Ágg B, Andova A, Arslan S, Baker A, Barteková M, Beis D, Betsou F, Wettinger SB, Bugarski B, Condorelli G, Silva GJJD, Danilin S, de Gonzalo-Calvo D, Buil A, Carmo-Fonseca M, Enguita FJ, Felekkis K, Ferdinandy P, Gyöngyösi M, Hackl M, Karaduzovic-Hadziabdic K, Hellemans J, Heymans S, Hlavackova M, Hoydal MA, Janković A, Jusic A, Kardassis D, Kerkelä R, Kuster GM, Lakkisto P, Leszek P, Lustrek M, Maegdefessel L, Martelli F, Novella S, O'Brien T, Papaneophytou C, Pedrazzini T, Pinet F, Popescu O, Potočnjak I, Robinson E, Sasson S, Scholz M, Simionescu M, Stoll M, Varga ZV, Vinciguerra M, Xuereb A, Yilmaz MB, Emanueli C, Devaux Y, on behalf of the EU-CardioRNA COST Action (CA17129). Catalyzing Transcriptomics Research in Cardiovascular Disease: The CardioRNA COST Action CA17129.. in Non-Coding RNA. 2019;5(2):31.
doi:10.3390/ncrna5020031 .

Gomes, Clarissa Pedrosa da C, Ágg, Bence, Andova, Andrejaana, Arslan, Serdal, Baker, Andrew, Barteková, Monika, Beis, Dimitris, Betsou, Fay, Wettinger, Stephanie Bezzina, Bugarski, Branko, Condorelli, Gianluigi, Silva, Gustavo José Justo da, Danilin, Sabrina, de Gonzalo-Calvo, David, Buil, Alfonso, Carmo-Fonseca, Maria, Enguita, Francisco J, Felekkis, Kyriacos, Ferdinandy, Peter, Gyöngyösi, Mariann, Hackl, Matthias, Karaduzovic-Hadziabdic, Kanita, Hellemans, Jan, Heymans, Stephane, Hlavackova, Markéta, Hoydal, Morten Andre, Janković, Aleksandra, Jusic, Amela, Kardassis, Dimitris, Kerkelä, Risto, Kuster, Gabriela M, Lakkisto, Päivi, Leszek, Przemyslaw, Lustrek, Mitja, Maegdefessel, Lars, Martelli, Fabio, Novella, Susana, O'Brien, Timothy, Papaneophytou, Christos, Pedrazzini, Thierry, Pinet, Florence, Popescu, Octavian, Potočnjak, Ines, Robinson, Emma, Sasson, Shlomo, Scholz, Markus, Simionescu, Maya, Stoll, Monika, Varga, Zoltan V, Vinciguerra, Manlio, Xuereb, Angela, Yilmaz, Mehmet Birhan, Emanueli, Costanza, Devaux, Yvan, on behalf of the EU-CardioRNA COST Action (CA17129), "Catalyzing Transcriptomics Research in Cardiovascular Disease: The CardioRNA COST Action CA17129." in Non-Coding RNA, 5, no. 2 (2019):31,
https://doi.org/10.3390/ncrna5020031 . .

TY  - JOUR
AU  - Janković, Aleksandra
AU  - Korać, Aleksandra
AU  - Buzadžić, Biljana
AU  - Stančić, Ana
AU  - Otašević, Vesna
AU  - Ferdinandy, Peter
AU  - Daiber, Andreas
AU  - Korać, Bato
PY  - 2017
UR  - http://radar.ibiss.bg.ac.rs/handle/123456789/6734
AB  - Insulin sensitivity and metabolic homeostasis depend on the capacity of adipose tissue to take up and utilize excess glucose and fatty acids. The key aspects that determine the fuel‐buffering capacity of adipose tissue depend on the physiological levels of the small redox molecule, nitric oxide (NO). In addition to impairment of NO synthesis, excessive formation of the superoxide anion (О2 •–) in adipose tissue may be an important interfering factor diverting the signalling of NO and other reactive oxygen and nitrogen species in obesity, resulting in metabolic dysfunction of adipose tissue over time. Besides its role in relief from superoxide burst, enhanced NO signalling may be responsible for the therapeutic benefits of different superoxide dismutase mimetics, in obesity and experimental diabetes models. This review summarizes the role of NO in adipose tissue and highlights the effects of NO/О2 •– ratio ‘teetering’ as a promising pharmacological target in the metabolic syndrome.
PB  - John Wiley & Sons, Inc
T2  - British Journal of Pharmacology
T1  - Targeting the NO/superoxide ratio in adipose tissue: relevance to obesity and diabetes management
IS  - 12
VL  - 174
DO  - 10.1111/bph.13498
SP  - 1570
EP  - 1590
ER  - 

@article{
author = "Janković, Aleksandra and Korać, Aleksandra and Buzadžić, Biljana and Stančić, Ana and Otašević, Vesna and Ferdinandy, Peter and Daiber, Andreas and Korać, Bato",
year = "2017",
abstract = "Insulin sensitivity and metabolic homeostasis depend on the capacity of adipose tissue to take up and utilize excess glucose and fatty acids. The key aspects that determine the fuel‐buffering capacity of adipose tissue depend on the physiological levels of the small redox molecule, nitric oxide (NO). In addition to impairment of NO synthesis, excessive formation of the superoxide anion (О2 •–) in adipose tissue may be an important interfering factor diverting the signalling of NO and other reactive oxygen and nitrogen species in obesity, resulting in metabolic dysfunction of adipose tissue over time. Besides its role in relief from superoxide burst, enhanced NO signalling may be responsible for the therapeutic benefits of different superoxide dismutase mimetics, in obesity and experimental diabetes models. This review summarizes the role of NO in adipose tissue and highlights the effects of NO/О2 •– ratio ‘teetering’ as a promising pharmacological target in the metabolic syndrome.",
publisher = "John Wiley & Sons, Inc",
journal = "British Journal of Pharmacology",
title = "Targeting the NO/superoxide ratio in adipose tissue: relevance to obesity and diabetes management",
number = "12",
volume = "174",
doi = "10.1111/bph.13498",
pages = "1570-1590"
}

Janković, A., Korać, A., Buzadžić, B., Stančić, A., Otašević, V., Ferdinandy, P., Daiber, A.,& Korać, B.. (2017). Targeting the NO/superoxide ratio in adipose tissue: relevance to obesity and diabetes management. in British Journal of Pharmacology
John Wiley & Sons, Inc., 174(12), 1570-1590.
https://doi.org/10.1111/bph.13498

Janković A, Korać A, Buzadžić B, Stančić A, Otašević V, Ferdinandy P, Daiber A, Korać B. Targeting the NO/superoxide ratio in adipose tissue: relevance to obesity and diabetes management. in British Journal of Pharmacology. 2017;174(12):1570-1590.
doi:10.1111/bph.13498 .

Janković, Aleksandra, Korać, Aleksandra, Buzadžić, Biljana, Stančić, Ana, Otašević, Vesna, Ferdinandy, Peter, Daiber, Andreas, Korać, Bato, "Targeting the NO/superoxide ratio in adipose tissue: relevance to obesity and diabetes management" in British Journal of Pharmacology, 174, no. 12 (2017):1570-1590,
https://doi.org/10.1111/bph.13498 . .